(VallonPharma) Shares of Vallon Pharmaceuticals Inc. fell more than 74% in pre-market on Monday after a weak study outcome for Lead Program, ADAIR, for ADHD treatment.
Vallon said that the study did not satisfy the primary end-point for a significant reduction in Emax Drug Liking for ADAIR vs. reference dextroamphetamine.
The company, however, noted that the trend was in favor of ADAIR, and all pharmacodynamic secondary endpoints were met with statistical significance.
Vallon President and CEO David Baker said that as the company gains more insight from further analysis of the study endpoints, it will outline the next steps in the development program.
VLON: NASDAQ is down -74.24% on premarket.
